Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA has appointed Sheila A. Stamps to its board of directors, effective immediately. With over 40 years of experience in strategic governance and operational management, Ms. Stamps has held leadership roles in both public and private sectors, including as a senior investment advisor for the New York State Comptroller. She serves on boards of multiple public companies and has a strong background in audit and finance. Following her appointment, IQVIA's board comprises 11 directors, ten of whom are independent.
IQVIA (NYSE:IQV) has appointed Leslie Wims Morris to its board of directors, effective immediately. Wims Morris brings over 25 years of financial services experience, currently serving as Managing Director and Head of Corporate Development at JPMorgan Chase. Her expertise includes managing strategic partnerships and participating in firmwide initiatives. CEO Ari Bousbib expressed confidence that her global experience will add valuable insight to the company. Wims Morris holds an MBA from Harvard and a BA in English from Yale.
Summary not available.
IQVIA (NYSE:IQV) has launched new Research Nursing and Phlebotomy services that enhance patient access and care during clinical trials. These services enable patients to receive professional care at home, improving outcomes and reducing costs. Ronan Brown, global head of Decentralized Trial Solutions, emphasized that this initiative reflects IQVIA's commitment to patient-centric research. The mobile workforce provides flexible support for clinical trials, enhancing patient experiences and protocol compliance while ensuring quality oversight and training. This innovation marks a significant step in decentralizing clinical trials.
Summary not available.
IQVIA (NYSE:IQV) has launched a new module, Grants and Funding Management, within its Orchestrated Customer Engagement (OCE) solutions. This module aims to provide life sciences companies a comprehensive tool to manage their global strategic giving programs, from grant submission to payment processing. The automated system enhances user experience and compliance, helping to streamline workflows and reduce errors. IQVIA continues to leverage its expertise to adapt to evolving market needs, promoting efficiency in funding request management.
IQVIA reported impressive financial results for Q3 2021, with revenue reaching $3,391 million, a 21.7% year-over-year increase. GAAP Net Income soared to $261 million, marking a 158.4% rise. Adjusted EBITDA stood at $728 million, up 20.5%. The company raised its full-year guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS. R&D Solutions contracted backlog grew 12.7% to $24.4 billion, with an expected $6.9 billion conversion to revenue in the next year. Overall, IQVIA demonstrated robust growth across all segments.
IQVIA Holdings Inc. (NYSE:IQV) will report its third-quarter 2021 financial results on October 21, 2021, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time the same day, with details available on the IQVIA Investor Relations website. The earnings release and financial information will also be posted online. Participants need to register in advance to join the call. IQVIA is a global leader in advanced analytics and clinical research services, employing around 74,000 people across more than 100 countries.
IQVIA Holdings Inc. (NYSE:IQV) will host an Analyst and Investor Conference on November 16, 2021, in New York City. The conference will start at 10:00 a.m. ET and end around 12:30 p.m. ET. Management will provide a business update, and registration is required for attendance. The live event will be accessible via webcast, with login details available on the IQVIA Investor Relations website starting November 9, 2021. A replay will be available the same day.
IQVIA has announced the opening of a 160,000-square-foot facility for its Q2 Solutions subsidiary in Research Triangle Park, North Carolina. This state-of-the-art lab will create up to 750 jobs over the next decade. The facility features advanced laboratory capabilities, including biomarker and genomics laboratories, and a Translational Science and Innovation Laboratory (TSAIL) to enhance drug development. These innovations aim to streamline R&D for biopharmaceutical companies, supporting faster drug development processes.